Fatality forces GENIZ to halt trial

Genetics Institute Inc. announced late Friday that it has suspended its Phase II study of recombinant human interleukin-12 (rhIL-12) in advanced kidney cancer following adverse events that led to the hospitalization of 10 patients and the death of one of those patients on Friday.

A total of 17 patients had been treated in the trial, which contains no placebo arm, before it was suspended Thursday morning. Patrick Gage, chief operating officer, said he couldn't yet give any details of the adverse events seen in the new study...